Analysts Offer Insights on Healthcare Companies: Danaher (DHR), 60 Degrees Pharmaceuticals, Inc. (SXTP) and BridgeBio Pharma (BBIO)
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Danaher (DHR), 60 Degrees Pharmaceuticals, Inc. (SXTP) and BridgeBio Pharma (BBIO) with bullish sentiments.
End of Quarter Sale - 50% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Danaher (DHR)
Bank of America Securities analyst Michael Ryskin maintained a Buy rating on Danaher today. The company’s shares closed last Tuesday at $188.52.
According to TipRanks.com, Ryskin is a 3-star analyst with an average return of
Currently, the analyst consensus on Danaher is a Strong Buy with an average price target of $264.62, representing a 41.7% upside. In a report issued on March 16, TipRanks – PerPlexity also reiterated a Buy rating on the stock with a $210.00 price target.
See the top stocks recommended by analysts >>
60 Degrees Pharmaceuticals, Inc. (SXTP)
In a report released today, Matthew Keller from H.C. Wainwright reiterated a Buy rating on 60 Degrees Pharmaceuticals, Inc., with a price target of $24.00. The company’s shares closed last Tuesday at $1.70, close to its 52-week low of $1.41.
According to TipRanks.com, Keller has 0 stars on 0-5 stars ranking scale with an average return of
60 Degrees Pharmaceuticals, Inc. has an analyst consensus of Moderate Buy, with a price target consensus of $24.00.
BridgeBio Pharma (BBIO)
In a report released today, Andrew Tsai from Jefferies maintained a Buy rating on BridgeBio Pharma, with a price target of $100.00. The company’s shares closed last Tuesday at $73.42.
According to TipRanks.com, Tsai is a 5-star analyst with an average return of
Currently, the analyst consensus on BridgeBio Pharma is a Strong Buy with an average price target of $101.72, which is a 44.9% upside from current levels. In a report issued on March 16, William Blair also maintained a Buy rating on the stock.
Read More on DHR:
Disclaimer & DisclosureReport an Issue
- Wix downgraded, TripAdvisor upgraded: Wall Street’s top analyst calls
- Danaher put volume heavy and directionally bearish
- Palantir upgraded, Workday downgraded: Wall Street’s top analyst calls
- Danaher’s Masimo Acquisition: Strategic Expansion in Hospital Diagnostics Supports Buy Rating
- Masimo downgraded to Neutral from Buy at BTIG
